SLS vs NVAX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SLS · Sellas Life Sciences$8.42 ▲ 6.85%
NVAX · Novavax$10.78 ▲ 10.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SLS +461.3%
- NVAX +51.6%
Head to head
| Metric | SLS | NVAX |
|---|---|---|
| Price | $8.42 | $10.78 |
| Change today | ▲ 6.85% | ▲ 10.22% |
| Market cap | $1.70B | $1.78B |
| Return, 3 months | -23.7% | +36.6% |
| Return, year to date | +123.3% | +60.4% |
| Return, 1 year | +429.6% | +44.9% |
| P/E (TTM) | -38.3 | -20.7 |
| P/B | 12.3 | -8.2 |
| P/E percentile vs own 5y | 7th | 11th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -76.3% |
| Net profit growth (YoY) | -45.5% | -150.1% |
| Gross margin | – | 78.6% |
| Operating margin | – | -32.9% |
| Net margin | – | -59.9% |
| Return on equity | -39.6% | – |
| Analyst target vs. price | +256.3% | -0.3% |
| Analyst buy share | 100% | 25% |
| RSI (14) | 37 | 52 |
| 30-day volatility | 108.8% | 109.4% |
| Max drawdown, 1 year | -49.0% | -34.6% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NVAX is the largest of the group by market value.
- SLS has returned the most over the past year.
- SLS carries the lowest trailing P/E.
- SLS has been the calmest stock over the last 30 days.